This opportunity is currently closed.
Sign up for Content alerts to stay informed when this or related funding opportunities are posted.
Development and Validation of Harmonized Methodologies to Measure NAD+ and Related Metabolites in Clinical Trials (U01 Clinical Trial Required)
The Development and Validation of Harmonized Methodologies to Measure NAD+ and Related Metabolites in Clinical Trials (U01 Clinical Trial Required) funding from the National Institutes of Health (NIH) invites applications to develop and validate the standardized protocols for measuring nicotinamide adenine dinucleotide (NAD+) and related metabolites levels in humans, including sample collection and storage, assays’ calibration, and standardization of measurements across different types of samples, such as plasma, tissue, or serum extracts, and validation of these protocols. Limited preclinical animal studies may be proposed, if such studies are an integral part of the application, and if they are needed to test the select elements of the standardized protocols in animal models before such protocols can be tested in humans. Applications selected for funding will be funded by individual awards, but all award recipients funded under this NOFO will be required to interact as a network and exchange information, including discussing progress, pitfalls, and issues that arise during implementation of the studies. Applications are open to research institutions, small business and other for-profit organizations in the USA. Foreign components of US institutions are also welcome to apply.
There is no fixed budget for the award but it must reflect the actual costs of the project. The typical project period is 5 years.
Opportunity number: RFA-AG-24-039
Letters of intent are due on October 2, 2023. Applications close on November 2, 2023.
November 2, 2023